Hara, A.; Watanabe, S.; Sawano, T.; Sonoda, Y.; Saito, H.; Ozaki, A.; Wakui, M.; Zhao, T.; Yamamoto, C.; Kobashi, Y.;
et al. The Anti-Nucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection for Hemodialysis Patients. Vaccines 2025, 13, 750.
https://doi.org/10.3390/vaccines13070750
AMA Style
Hara A, Watanabe S, Sawano T, Sonoda Y, Saito H, Ozaki A, Wakui M, Zhao T, Yamamoto C, Kobashi Y,
et al. The Anti-Nucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection for Hemodialysis Patients. Vaccines. 2025; 13(7):750.
https://doi.org/10.3390/vaccines13070750
Chicago/Turabian Style
Hara, Akemi, Shun Watanabe, Toyoaki Sawano, Yuki Sonoda, Hiroaki Saito, Akihiko Ozaki, Masatoshi Wakui, Tianchen Zhao, Chika Yamamoto, Yurie Kobashi,
and et al. 2025. "The Anti-Nucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection for Hemodialysis Patients" Vaccines 13, no. 7: 750.
https://doi.org/10.3390/vaccines13070750
APA Style
Hara, A., Watanabe, S., Sawano, T., Sonoda, Y., Saito, H., Ozaki, A., Wakui, M., Zhao, T., Yamamoto, C., Kobashi, Y., Abe, T., Kawamura, T., Sugiyama, A., Nakayama, A., Kaneko, Y., Shimmura, H., & Tsubokura, M.
(2025). The Anti-Nucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection for Hemodialysis Patients. Vaccines, 13(7), 750.
https://doi.org/10.3390/vaccines13070750
